Stock XTNT XTANT MEDICAL HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xtant Medical Holdings, Inc.

Equities

XTNT

US98420P3082

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.8946 USD -3.81% Intraday chart for Xtant Medical Holdings, Inc. -1.58% -20.83%
Apr. 30 Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds CI
Apr. 01 Xtant Medical Files $150 Million Mixed Shelf; Shares Fall MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 71% by 2026.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
XTANT MEDICAL HOLDINGS, INC. Stock Xtant Medical Holdings, Inc.
-20.83% 121M -
STRYKER CORPORATION Stock Stryker Corporation
+12.37% 129B
A-
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.23% 10.77B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+2.17% 9.05B
C
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+18.79% 7.38B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+20.77% 4.88B
B+
AXONICS, INC. Stock Axonics, Inc.
+6.97% 3.41B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-1.41% 3.07B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-5.07% 2.24B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-4.22% 2.12B -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XTNT Stock
  4. Ratings Xtant Medical Holdings, Inc.